MRNS Earnings

MRNS reported its FY2024Q3 earnings on 2024-11-12, showcasing a revenue of 8.54M against an estimate of 9.42M, resulting in a -9.35% surprise. The EPS was -0.42, surpassing the expected -0.44 by 4.55% . The stock experienced a 2.99% price change on the earnings day and a -8.06% change over the next five days, reflecting market reactions to the results.

Following MRNS's FY2024Q3 earnings announcement on 2024-11-12, the stock price moved by 2.99% on the day of the release. Over the subsequent five days, it saw a -8.06% change. Historically, MRNS's stock price tends to shift by an average of -0.10% in the 10 days leading up to earnings and -3.93% in the 10 days following, providing insight into potential market.

For 2024/Q4, analysts estimate MRNS’s annual revenue to reach 10.59M, while the EPS is projected at undefined. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by % and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between MRNS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for were No Change by %, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MRNS's stock price typically moves by -0.10% in the 10 days before its earnings and -3.93% in the 10 days after. For the upcoming 2024/Q4 earnings, analysts expect an EPS of undefined and revenue of 10.59M.

The earnings call presents mixed signals. While financial performance shows increased expenses and net loss, there is optimism in product development and market strategy, especially with reimbursement dynamics and new drug developments. The Q&A reveals strong support for ZTALMY and potential for new products, but management's lack of clarity on some trial details raises concerns. Overall, the sentiment is balanced, leading to a neutral prediction.